---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-142019"
form_type: "8-K"
ticker: "ELVN"
cik: "0001672619"
company_name: "Enliven Therapeutics, Inc."
filed_at: "2023-05-11T23:59:59+00:00"
generated_at: "2026-06-15T04:16:38.478428+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Enliven Therapeutics Q1 net loss $14.7M; cash $292.1M; dosed first patient in ELVN-002 Phase 1

## Summary
- Net loss of $14.7M for Q1 2023 vs $8.7M in Q1 2022; R&D expenses $11.9M, G&A $4.5M.
- Cash and equivalents $292.1M as of March 31, 2023, expected to fund operations into early 2026.
- Dosed first patient in Phase 1 trial of ELVN-002 for HER2-altered NSCLC and other solid tumors.
- Enrollment progressing in Phase 1 trial of ELVN-001 for CML; initial safety/efficacy data expected in 2024.
- Completed merger with Imara Inc. in February 2023; shares now trade as ELVN on Nasdaq.

## SEC filing metadata
- accession: 0001193125-23-142019
- form_type: 8-K
- ticker: ELVN
- cik: 0001672619
- company_name: Enliven Therapeutics, Inc.
- filed_at: 2023-05-11T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1672619/000119312523142019/0001193125-23-142019-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1672619/000119312523142019/d421860d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-142019
- JSON: https://secwatch.observer/filing/0001193125-23-142019.json
- Plain text: https://secwatch.observer/filing/0001193125-23-142019.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.